Literature DB >> 3820228

Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.

J D Conley, H Kohn.   

Abstract

Structural analogues of the potent known anticonvulsant agent N-acetyl-DL-alanine N-benzylamide (1a) have been prepared (16 examples). The pharmacological activities of these products were evaluated in the maximal electroshock seizure (MES), the subcutaneous pentylenetetrazole seizure threshold (sc Met), and the rotorod (Tox) tests. The median effective doses (ED50) and the median toxic doses (TD50) for the most active compounds by both intraperitoneal and oral administration are reported. The most active compounds were N-acetyl-DL-phenylglycine N-benzylamide (1d) and N-acetyl-DL-alanine N-m-fluorobenzylamide (1m) along with the parent compound 1a. The ED50 values in the MES test for these three compounds compared well with phenobarbital, while their high TD50 values contributed to their large protective indexes, which approached that of phenytoin. When tested against four convulsant agents, compounds 1a and 1d displayed activity profiles significantly different from those reported for conventionally used antiepileptic drugs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3820228     DOI: 10.1021/jm00386a021

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  The structure-activity relationship of the 3-oxy site in the anticonvulsant (R)-N-benzyl 2-acetamido-3-methoxypropionamide.

Authors:  Pierre Morieux; Christophe Salomé; Ki Duk Park; James P Stables; Harold Kohn
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

Review 2.  Diverse mechanisms of antiepileptic drugs in the development pipeline.

Authors:  Michael A Rogawski
Journal:  Epilepsy Res       Date:  2006-04-18       Impact factor: 3.045

3.  Defining the structural parameters that confer anticonvulsant activity by the site-by-site modification of (R)-N'-benzyl 2-amino-3-methylbutanamide.

Authors:  Amber M King; Marc De Ryck; Rafal Kaminski; Anne Valade; James P Stables; Harold Kohn
Journal:  J Med Chem       Date:  2011-09-13       Impact factor: 7.446

4.  Merging Structural Motifs of Functionalized Amino Acids and α-Aminoamides Results in Novel Anticonvulsant Compounds with Significant Effects on Slow and Fast Inactivation of Voltage-gated Sodium Channels and in the Treatment of Neuropathic Pain.

Authors:  Yuying Wang; Sarah M Wilson; Joel M Brittain; Matthew S Ripsch; Christophe Salomé; Ki Duk Park; Fletcher A White; Rajesh Khanna; Harold Kohn
Journal:  ACS Chem Neurosci       Date:  2011-06-15       Impact factor: 4.418

5.  Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.

Authors:  Christophe Salomé; Elise Salomé-Grosjean; James P Stables; Harold Kohn
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

6.  Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.

Authors:  Christophe Salomé; Elise Salomé-Grosjean; Ki Duk Park; Pierre Morieux; Robert Swendiman; Erica DeMarco; James P Stables; Harold Kohn
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

7.  Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.

Authors:  Ki Duk Park; Pierre Morieux; Christophe Salomé; Steven W Cotten; Onrapak Reamtong; Claire Eyers; Simon J Gaskell; James P Stables; Rihe Liu; Harold Kohn
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

8.  Computational Characterization of Nylon 4, a Biobased and Biodegradable Polyamide Superior to Nylon 6.

Authors:  Yuichiro Fukuda; Yuji Sasanuma
Journal:  ACS Omega       Date:  2018-08-20

9.  Synthesis, Anticonvulsant, Antimicrobial and Analgesic activity of Novel 1,2,4-Dithiazoles.

Authors:  A Gupta; P Mishra; S K Kashaw; V Jatav
Journal:  Indian J Pharm Sci       Date:  2008 Jul-Aug       Impact factor: 0.975

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.